By ThinkSabio #ThinkSabio Latest News
NOVO NORDISK - TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING A STATISTICALLY SIGNIFICANT AND SUPERIOR WEIGHT LOSS AT WEEK 72 WITH SEMAGLUTIDE 7.2 MG VERSUS PLACEBO.
Subscribe
for ThinkSabio Updates !
We'll keep you up to date about our Stocks, Sec Alerts , Trendings Stocks etc..